Global Information
회사소개 | 문의 | 비교리스트

뇌(치명적) 말라리아 : 파이프라인 리뷰

Cerebral (Fatal) Malaria - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 410992
페이지 정보 영문 37 Pages
가격
US $ 2,000 ₩ 2,433,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,866,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,299,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


뇌(치명적) 말라리아 : 파이프라인 리뷰 Cerebral (Fatal) Malaria - Pipeline Review, H2 2016
발행일 : 2016년 12월 페이지 정보 : 영문 37 Pages

뇌말라리아는 가장 위험하고 생명을 위협하는 종류의 말라리아로, 뇌에 영향을 미칩니다. 열대열말라리아원충이라는 기생 원생동물에 의해 발생합니다. 말라리아원충은 감염된 모기에 물림으로써 사람에 기생합니다. 증상은 열, 두통, 근육통, 저혈압증, 혼수, 경련 등입니다. 치료에는 항말라리아약, 항경련약, 항염증약 등을 처방합니다.

뇌(치명적) 말라리아 치료제 개발 파이프라인의 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에 의해 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 최신 뉴스 및 발표와 함께 정리하여 전해드립니다.

서론

  • 조사 범위

뇌(치명적) 말라리아 개요

치료제 개발

  • 파이프라인 제품;개요
  • 파이프라인 제품;비교 분석

기업에서 개발중인 치료제

대학/기관에서 연구중인 치료제

파이프라인 제품의 개요

  • 임상시험 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

대학/연구기관에서 연구중인 제품

치료제 개발에 참여하고 있는 기업

  • Callaghan Innovation Research Ltd
  • Eisai Co Ltd
  • Lipocure Ltd

치료제 평가

  • 단일요법 제품
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

  • E-6446
  • 말라리아 백신
  • 말라리아 백신 6
  • 인산나트륨 메틸프레드니솔론
  • 뉴레귤린 1
  • RRX-001
  • 말라리아용 히포크산틴포스포리보실전달효소 저해제

휴지중인 프로젝트

부록

도표

KSA 17.02.15

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cerebral (Fatal) Malaria - Pipeline Review, H2 2016, provides an overview of the Cerebral (Fatal) Malaria (Infectious Disease) pipeline landscape.

Cerebral malaria is the most dangerous and life-threatening form of malaria that affects the brain. It is caused by plasmodium falciparum, a protozoan parasite. Plasmodium gets transmitted to human via infected mosquito bites.Symptoms include fever, head ache, muscle pain, low blood pressure, coma and convulsions. Treatment includes antimalarial, antiseizure and anti inflammatory medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cerebral (Fatal) Malaria - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cerebral (Fatal) Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cerebral (Fatal) Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cerebral (Fatal) Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 4 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Cerebral (Fatal) Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cerebral (Fatal) Malaria (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Cerebral (Fatal) Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cerebral (Fatal) Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cerebral (Fatal) Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cerebral (Fatal) Malaria (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cerebral (Fatal) Malaria (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cerebral (Fatal) Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cerebral (Fatal) Malaria Overview
  • Therapeutics Development
    • Pipeline Products for Cerebral (Fatal) Malaria - Overview
    • Pipeline Products for Cerebral (Fatal) Malaria - Comparative Analysis
  • Cerebral (Fatal) Malaria - Therapeutics under Development by Companies
  • Cerebral (Fatal) Malaria - Therapeutics under Investigation by Universities/Institutes
  • Cerebral (Fatal) Malaria - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Cerebral (Fatal) Malaria - Products under Development by Companies
  • Cerebral (Fatal) Malaria - Products under Investigation by Universities/Institutes
  • Cerebral (Fatal) Malaria - Companies Involved in Therapeutics Development
    • Callaghan Innovation Research Ltd
    • Eisai Co Ltd
    • Lipocure Ltd
  • Cerebral (Fatal) Malaria - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • E-6446 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • malaria vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • malaria vaccine 6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • methylprednisolone sodium phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • neuregulin-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RRX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Hypoxanthine Phosphoribosyltransferase for Malaria - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cerebral (Fatal) Malaria - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cerebral (Fatal) Malaria, H2 2016
  • Number of Products under Development for Cerebral (Fatal) Malaria - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Cerebral (Fatal) Malaria - Pipeline by Callaghan Innovation Research Ltd, H2 2016
  • Cerebral (Fatal) Malaria - Pipeline by Eisai Co Ltd, H2 2016
  • Cerebral (Fatal) Malaria - Pipeline by Lipocure Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Cerebral (Fatal) Malaria - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Cerebral (Fatal) Malaria, H2 2016
  • Number of Products under Development for Cerebral (Fatal) Malaria - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top
전화 문의
F A Q